ANAPP3 | CAS#58775-41-0 | Inhibitor

MedKoo Cat#: 463052 | Name: ANAPP3

Description:

WARNING: This product is for research use only, not for human or veterinary use.

ANAPP3 is a P2x-purinoceptor antagonist. It affects contractions in various muscle groups and tissues.

Chemical Structure

ANAPP3

CAS#58775-41-0

Theoretical Analysis

MedKoo Cat#: 463052

Name: ANAPP3

CAS#: 58775-41-0

Chemical Formula: C19H23N10O16P3

Exact Mass: 740.0506

Molecular Weight: 740.37

Elemental Analysis: C, 30.82; H, 3.13; N, 18.92; O, 34.58; P, 12.55

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

ANAPP3; Arylazido aminopropionyl ATP; Arylazidoaminopropyladenosine triphosphate;

IUPAC/Chemical Name

(((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl triphosphoric) 3-((4-azido-2-nitrophenyl)amino)propanoic anhydride

InChi Key

WIDPMFLUERJOSK-USLZMYRNSA-N

InChi Code

InChI=1S/C19H23N10O16P3/c20-17-14-18(24-7-23-17)28(8-25-14)19-16(32)15(31)12(42-19)6-41-48(40,45-47(38,39)44-46(35,36)37)43-13(30)3-4-22-10-2-1-9(26-27-21)5-11(10)29(33)34/h1-2,5,7-8,12,15-16,19,22,31-32H,3-4,6H2,(H,38,39)(H2,20,23,24)(H2,35,36,37)/t12-,15-,16-,19-,48?/m1/s1

SMILES Code

Nc1c2ncn([C@@H]3O[C@@H]([C@H]([C@H]3O)O)COP(OC(CCNc4c([N+]([O-])=O)cc(N=[N+]=[N-])cc4)=O)(OP(O)(OP(O)(O)=O)=O)=O)c2ncn1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 740.37 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Chapal J, Hillaire-Buys D, Bertrand G, Pujalte D, Petit P, Loubatières- Mariani MM. Comparative effects of adenosine-5'-triphosphate and related analogues on insulin secretion from the rat pancreas. Fundam Clin Pharmacol. 1997;11(6):537-45. doi: 10.1111/j.1472-8206.1997.tb00858.x. PMID: 9444521. 2: Kennedy C. ATP as a cotransmitter in perivascular sympathetic nerves. J Auton Pharmacol. 1996 Dec;16(6):337-40. doi: 10.1111/j.1474-8673.1996.tb00048.x. PMID: 9131411. 3: Venkova K, Krier J. Stimulation of lumbar sympathetic nerves evokes contractions of cat colon circular muscle mediated by ATP and noradrenaline. Br J Pharmacol. 1993 Nov;110(3):1260-70. doi: 10.1111/j.1476-5381.1993.tb13951.x. PMID: 7905343; PMCID: PMC2175786. 4: Lamport-Vrana SJ, Vrana KE, Fedan JS. Involvement of ecto-phosphoryl transfer in contractions of the smooth muscle of the guinea pig vas deferens to adenosine 5'-triphosphate. J Pharmacol Exp Ther. 1991 Jul 1;258(1):339-48. PMID: 2072306. 5: Fedan JS, Lamport SJ. Two dissociable phases in the contractile response of the guinea pig isolated vas deferens to adenosine triphosphate. J Pharmacol Exp Ther. 1990 Jun;253(3):993-1001. PMID: 2359034. 6: Fujioka M, Cheung DW. Autoregulation of neuromuscular transmission in the guinea-pig saphenous artery. Eur J Pharmacol. 1987 Jul 9;139(2):147-53. doi: 10.1016/0014-2999(87)90246-9. PMID: 2820758. 7: Cheung DW, Fujioka M. Inhibition of the excitatory junction potential in the guinea-pig saphenous artery by ANAPP3. Br J Pharmacol. 1986 Sep;89(1):3-5. doi: 10.1111/j.1476-5381.1986.tb11114.x. PMID: 3801776; PMCID: PMC1917035. 8: Frew R, Lundy PM. Arylazido aminopropionyl ATP (ANAPP3): interaction with adenosine receptors in longitudinal smooth muscle of the guinea-pig ileum. Eur J Pharmacol. 1986 Apr 29;123(3):395-400. doi: 10.1016/0014-2999(86)90714-4. PMID: 3013654. 9: Theobald RJ Jr, Hoffman V. Long-lasting blockade of P2-receptors of the urinary bladder in vivo following photolysis of arylazido aminopropionyl ATP, a photoaffinity label. Life Sci. 1986 Apr 28;38(17):1591-5. doi: 10.1016/0024-3205(86)90498-4. PMID: 3010020. 10: Theobald RJ Jr. The effect of arylazido aminopropionyl ATP (ANAPP3) on inhibition of pelvic nerve evoked contractions of the cat urinary bladder. Eur J Pharmacol. 1986 Jan 29;120(3):351-4. doi: 10.1016/0014-2999(86)90476-0. PMID: 3753940. 11: White TD, Chaudhry A, Vohra MM, Webb D, Leslie RA. Characteristics of P2 (nucleotide) receptors mediating contraction and relaxation of rat aortic strips: possible physiological relevance. Eur J Pharmacol. 1985 Nov 26;118(1-2):37-44. doi: 10.1016/0014-2999(85)90660-0. PMID: 3002811. 12: Fedan JS, Hogaboom GK, O'Donnell JP, Jeng SJ, Guillory RJ. Interaction of [3H]arylazido aminopropionyl ATP ([3H]ANAPP3) with P2-purinergic receptors in the smooth muscle of the isolated guinea-pig vas deferens. Eur J Pharmacol. 1985 Jan 15;108(1):49-61. doi: 10.1016/0014-2999(85)90282-1. PMID: 2984018. 13: Burnstock G, Kennedy C. Is there a basis for distinguishing two types of P2-purinoceptor? Gen Pharmacol. 1985;16(5):433-40. doi: 10.1016/0306-3623(85)90001-1. PMID: 2996968. 14: Sneddon P, Westfall DP, Colby J, Fedan JS. A pharmacological investigation of the biphasic nature of the contractile response of rabbit and rat vas deferens to field stimulation. Life Sci. 1984 Nov 5;35(19):1903-12. doi: 10.1016/0024-3205(84)90470-3. PMID: 6492999. 15: Fedan JS, Hogaboom GK, O'Donnell JP. Comparison of the effects of apamin, a Ca2+-dependent K+ channel blocker, and arylazido aminopropionyl ATP (ANAPP3), a P2-purinergic receptor antagonist, in the guinea-pig vas deferens. Eur J Pharmacol. 1984 Sep 17;104(3-4):327-34. doi: 10.1016/0014-2999(84)90409-6. PMID: 6094219. 16: Longhurst PA, Belis JA, O'Donnell JP, Galie JR, Westfall DP. A study of the atropine-resistant component of the neurogenic response of the rabbit urinary bladder. Eur J Pharmacol. 1984 Apr 6;99(4):295-302. doi: 10.1016/0014-2999(84)90136-5. PMID: 6145602. 17: Sneddon P, Westfall DP. Pharmacological evidence that adenosine triphosphate and noradrenaline are co-transmitters in the guinea-pig vas deferens. J Physiol. 1984 Feb;347:561-80. doi: 10.1113/jphysiol.1984.sp015083. PMID: 6142947; PMCID: PMC1199464. 18: Theobald RJ Jr. The effect of arylazido aminopropionyl ATP on atropine resistant contractions of the cat urinary bladder. Life Sci. 1983 May 23;32(21):2479-84. doi: 10.1016/0024-3205(83)90374-0. PMID: 6855450. 19: Westfall DP, Fedan JS, Colby J, Hogaboom GK, O'Donnell JP. Evidence for a contribution by purines to the neurogenic response of the guinea-pig urinary bladder. Eur J Pharmacol. 1983 Mar 4;87(4):415-22. doi: 10.1016/0014-2999(83)90080-8. PMID: 6406237. 20: O'Donnell JP, Hogaboom GK, Fedan JS. Comparison of photoaffinity labeling of P2-purinergic receptors of isolated guinea-pig vas deferens by arylazido aminopropionyl ATP and by arylazido aminobutyryl ATP. Eur J Pharmacol. 1983 Jan 21;86(3-4):435-40. doi: 10.1016/0014-2999(83)90193-0. PMID: 6299761.